Cochrane · systematic review · CD013579
Treatment options for progression or recurrence of glioblastoma: a network meta‐analysis
McBain, C, Lawrie, TA, Rogozińska, E, et al. · Cochrane Database of Systematic Reviews · 2021 · Cochrane Library
Gynaecological, Neuro-oncology and Orphan CancerAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
12
current version
GRADE rated
7
No studies
2
Included studies
NR
No studies 2 · 16.7%Ungraded 3 · 25%Very low 0 · 0%Low 3 · 25%Moderate 0 · 0%High 4 · 33.3%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Summary of overall survival findings
Population: people with first recurrence of glioblastoma Interventions: bevacizumab (BEV), BEV + lomustine (LOM), regorafenib (REG), fotemustine (FOM), ABT414 + temozolomide (TMZ); BEV + irinotecan (IRI), BEV + onartuzumab (ONA), cediranib (CED), CED + LOM Comparison: lomustine Outcome: overall survivalÂ
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
All intervention options | no estimate extracted | NR | No studies |
Summary of progression‐free survival findings
Population: people with first recurrence of glioblastoma Interventions: bevacizumab (BEV), BEV + lomustine (LOM), regorafenib (REG), BEV + irinotecan (IRI), BEV + onartuzumab (ONA), cediranib (CED), CED+LOM Comparison: lomustine Outcome: Progression‐free survivalÂ
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
All intervention options | no estimate extracted | NR | No studies |
Summary of findings for severe adverse events ‐ 2
Population: people with any recurrence of glioblastoma Interventions: bevacizumab (BEV) Comparison: bevacizumab 9BEV), BEV+carboplatin (CAB), BEV+dasatinib (DAS), BEV+irinotecan (IRI), BEV+onartuzumab (ONA), BEV+TRC105, BEV+VB111, Fotemustine (FOM), BEV+HSPPC96 vaccine Outcome: severe adverse events
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Outcomes (5 RCTs, 1024 participants) | no estimate extracted | 5 studies · 1024 participants | Ungraded |
BEV(8 RCTs; 498 participants) | no estimate extracted | 8 studies · 498 participants | Ungraded |
FOM (1 RCT, 32 participants) | RR 0.44 [0.11, 1.72] | 1 study · 32 participants | Ungraded |
BEV+HSPPC96 1 RCTs; 53 participants) | RR 1.01 [0.33, 3.1] | 1 study · 96 participants | Low |
BEV+ONA(1 RCT; 64 participants) | RR 1.17 [0.57, 2.39] | 1 study · 64 participants | Low |
BEV+CAB (1 RCT; 58 participants) | RR 1.27 [0.61, 2.66] | 1 study · 58 participants | Low |
BEV+DAS (2 RCTs, 83 participants) | RR 0.52 [0.69, 3.34] | 2 studies · 83 participants | High |
BEV+IRI (1 RCT, 79 participants) | RR 2.22 [1.19, 4.18] | 1 study · 79 participants | High |
BEV+VB111 (1 RCT, 128 participants) | RR 3.77 [2.25, 6.33] | 1 study · 111 participants | High |
BEV+TRC 105 (1 RCT, 49 participants) | RR 6.86 [2.55, 18.41] | 1 study · 105 participants | High |